Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (GB:0A4M)
LSE:0A4M
Dexcom (0A4M) Share Price & Analysis
1 Followers
0A4M Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$74.71 - $141.97
Previous Close$125.74
Volume1.70K
Average Volume (3M)3.76K
Market Cap
$49.45B
Enterprise Value$51.42B
Total Cash (Recent Filing)$566.30M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)N/A
Beta0.81
Next Earnings
Jul 25, 2024EPS Estimate
$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding385,515,421
10 Day Avg. Volume326
30 Day Avg. Volume3,757
Standard Deviation0.12
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)25.11
Price to Sales (P/S)28.13
Price to Cash Flow (P/CF)89.70
P/FCF Ratio139.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.19
Enterprise Value/Gross Profit22.46
Enterprise Value/Ebitda55.80
Forecast
1Y Price Target
$154.13Price Target Upside22.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Dexcom News
PremiumStock Analysis & Ideas
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDXCM reported 1Q24 sales of $921MM, surpassing consensus estimates and demonstrating strong growth.
Market ExpansionExpansion into new international markets with DexCom ONE on G7’s platform is contributing to the company's growth.
Product LaunchStelo's upcoming US launch and over-the-counter approval present new market opportunities and potential for revenue expansion.
Bears Say
Legal IssuesDexcom faces a legal challenge for infringing a patent related to inserter technology, which could impact their market position and financial stability.
Product CompetitivenessRoche's Accu-Chek SmartGuide CGM has a higher MARD compared to competitors, reducing its competitive edge in the continuous glucose monitoring market.
Product ReliabilityA notable percentage of sensors fail to last the full advertised duration, raising concerns about the reliability and cost-effectiveness of the product.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.82% Insiders
35.12% Mutual Funds
25.01% Other Institutional Investors
37.05% Public Companies and
Individual Investors
0A4M FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest share price was $74.71 and its highest was $141.97 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 25, 2024 which is in 87 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Apr 25, 2024. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.271 by $0.049.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.39.
How many shares outstanding does Dexcom have?
Dexcom has 397,683,840 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.32 in its last earnings report, beating expectations of $0.271. Following the earnings report the stock price went down -8.732%.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 2B.
---
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.13 (22.58% Upside)
$154.13 (22.58% Upside)
Blogger Sentiment
Bullish
GB:0A4M Sentiment 86%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.47%
12-Months-Change
Fundamentals
Return on Equity
28.54%
Trailing 12-Months
Asset Growth
17.52%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
0A4M Company Deck
---
0A4M Earnings Call
Q1 2024
0:00 / 0:00
---
0A4M Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
0A4M Stock 12 Months Forecast
Average Price Target
$154.13
▲(22.58% Upside)
Technical Analysis
Best Analysts Covering 0A4M
1 Year
1 Year Success Rate
16/20 ratings generated profit
1 Year Average Return
+36.98%
reiterated a buy rating 3 days ago
Copying Mathew Blackman's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +36.98% per trade.
---